Posted on

Blackhawk’s Terp Wholesale LLC Reports Unaudited CDN$1,644,043 in Gross Revenue for First Five Months Ended May 31st, 2022

Blackhawk’s Terp Wholesale LLC Reports Unaudited CDN$1,644,043 in Gross Revenue for First Five Months Ended May 31st, 2022

Vancouver, British Columbia – TheNewswire – June 16th, 2022 – Blackhawk Growth Corp. (the “Company”) (CSE:BLR); (Frankfurt:0JJ) is pleased to provide an update on the operations of its wholly owned subsidiary, TERP Wholesale, LLC (“TERP”).  

For the five months beginning January 1st, 2022 ending May 31st, 2022, TERP reported unaudited CDN dollar results as follows:

Gross Revenue        $ 1,644,043

Gross Profit                $    842,921

TERP has been scaling operations and significant growth is expected to continue.

TERP is in its fourth year of operations and has seen consistent revenue growth in each year of operations. Readers are cautioned that these figures are prepared by management and are unaudited.  Actual results may defer once an audit has been completed.

Operations Update

TERP has expanded its square footage and is outfitting it with machinery to expand co-packing and overall production. These efficiency increases have not only allowed for more sales and production but increased profitability as well. TERP launching its retail delivery service beginning in Sacramento, California and expanding to statewide delivery in time. TERP’s infusion center is another path that will see product lines and revenues grow.

“TERP has been performing extremely well” said Frederick Pels, CEO of Blackhawk Growth. “They have shown impactful growth in gross revenue and with their new efficiencies, larger footprint, and retail delivery coming online, I am certain we will see further increases over the coming months. I cannot wait to share our progress with our shareholders as it becomes available.”  

About TERP Wholesale LLC

TERP is a fully licensed distribution center in the state of California. TERP packages and manufacturers some of the highest quality exotic brands and high THC products in the state of California. The team encompasses several distribution professionals, guided by a proven leadership with extensive experience in cannabis and quality-assured distribution. Current brands include, but are not limited to Sunshine Delight, Norcal’s Finest, California Cannabis, and Scoopz.

In addition, TERP provides supply chain solutions to the industry with the use of innovative technology, information management experts, security specialists, and sales/marketing professionals. Utilizing proven distribution methods, TERP’s model is based on a perishable supply chain strategy that emphasizes the importance of quality assurance and customer satisfaction.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes TERP Wholesale, Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Blum Distributors Ltd., NuWave Foods, MindBio Therapeutics, Digital Mind Technology as well as an equity position in Gaia Grow Corp. (CSE:GAIA) .

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Corporation within the meaning of applicable securities laws. The Corporation provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Corporation ’s public filings under the Corporation’s SEDAR profile at www.sedar.com. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk Appoints Justin Hanka as Chairman of The Board

Blackhawk Appoints Justin Hanka as Chairman of The Board

Vancouver, British Columbia – TheNewswire – June 06, 2022 – Blackhawk Growth Corp. (the “Company”) (CSE:BLR) (OTC:BLRZF) (Frankfurt:0JJ) is pleased to announce  the appointment of investment banker Justin Hanka as Director and Chairman of the Board of Directors to help execute corporate transactions in Blackhawk.

Mr Hanka has over 25 years of corporate transaction experience including cross border M&A, capital raising and equity capital markets in Australia and North America. Justin brings a wealth of sector expertise in insurance and financial services, ecommerce, fintech, health, pharma and medtech. Mr Hanka currently serves as Non-Executive Director of EonX, (CSE: EONX), a financial technology company and Goldcar Rental Australia & NZ, a Europcar company (PAR:EUCAR).  Mr. Hanka is also the Co-founder and Executive Director of Blackhawk’s wholly-owned subsidiary, MindBio Therapeutics (“MindBio”).

Previously Mr Hanka was Chief Operating Officer of iSelect (ASX:ISU) where he was instrumental in creating the commercial relationships and operational structures to drive the company’s revenue growth from zero to $100m+ in just a few years.  He previously served as Chief Executive Officer of HelpMeChoose which was acquired by ASX listed Mortgage Choice, subsequently acquired by the largest online realestate company in Australia, REA Group Limited (ASX:REA), with a market capitalization of $15B.

As Chairman and Director of Blackhawk, Mr. Hanka will drive several strategic initiatives to grow shareholder value. This includes sourcing new deal flow, executing on M&A and spin outs of Blackhawk’s existing portfolio and assisting with financing activities.

As incoming Chairman, Mr Hanka says, “As an investment issuer, Blackhawk is one of a handful of companies listed in Canada that can acquire, incubate and sell or spinout a new listing from its portfolio. The upcoming spin-out of MindBio, is a significant milestone and achievement for the Company and it demonstrates the value it can create for shareholders who receive a one for one shareholding in the newly listed entity.  I look forward to working with the board to transform Blackhawk into a premium investment issuer in the capital markets”.

“Justin Hanka is a tremendous addition to the board” said Frederick Pels, CEO of Blackhawk. “His experience and commitment to Blackhawk will be relied upon as we continue to reach milestones and add shareholder value. On behalf of the board and myself, I would like to welcome Justin Hanka and we look forward to working with him.”

Scott Seguin and Dave Antony have resigned from the Board of Directors due to other business commitments. The Company wishes to thank them for their service.

Spinout of MindBio Therapeutics

The Company also announces that it continues to move forward with the planned spinout of MindBio Therapeutics.  To ensure sufficient time for regulatory review of the spinout, the Company has elected to move the date for the meeting of shareholders to approve the spinout until July 15, 2022.  Further details regarding the spinout and the meeting will be made available in an information circular mailed to shareholders of record and posted under the profile for Blackhawk on SEDAR (www.sedar.com).  Completion of the spinout remains subject to the receipt of shareholder, regulatory and court approvals.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes TERP Wholesale, Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods, MindBio Therapeutics, Digital Mind Technology, Blum Distributors Ltd. as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Corporation within the meaning of applicable securities laws. The Corporation provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Corporation ’s public filings under the Corporation’s SEDAR profile at www.sedar.com. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawk Growth Files Quarter Ended March 31, 2022 Financials and Reports Increase in Value of its Portfolio by 8.8% Quarter Over Quarter

Blackhawk Growth Files Quarter Ended March 31, 2022 Financials and Reports Increase in Value of its Portfolio by 8.8% Quarter Over Quarter

Vancouver, British Columbia – TheNewswire – May 30, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company”), is pleased to announce that the financial statements and MD&A for its first quarter ended March 31, 2022 have been filed on Sedar.

Highlights for the quarter ended March 31, 2022:

  • Blackhawk acquires remaining 49% of Stable Foods Inc. Stable Foods is in development of shelf stable deserts that will be launched through distribution agreements once products are retail ready.  
  • MindBio Therapeutics Pyt Ltd., intent is to spin out on a 1:1 basis  
  • TERP Wholesale begins retail delivery and continues to develop further revenue streams  
  • As at March 31, 2022, Blackhawk held $27,043,266 in current investments, a 8.8% increase from the value at December 31, 2021 
  • As at March 31, 2022, NAV per share was $0.39  

Blackhawk Growth Corp. (“Blackhawk” or the “Company”) continues to review both equity and debt investment opportunities. The Company has focused its investments in the health, cannabis and CBD industries, in both Canada and the US.

“Our portfolio of companies continue to show growth and value,” says Frederick Pels, CEO of Blackhawk Growth Corp. “I look forward to updating shareholders as we work to execute, expand and deliver even more value from our initiatives over the course of the year.”

As at March 31, 2022 the Company’s equity investments consist of the following:

CompanyCostFair Value
 $$
MindBio Therapeutics11,826,63811,826,638
Digital Mind5,370,0005,370,000
Terp Wholesale, LLC.2,500,0002,500,000
SAC Pharma Partners Inc.1,890,0001,890,000
Gaia Grow Corp.1,500,000450,000
Noble Line Inc.1,050,4701,050,470
Trip Pharma Inc.1,120,4031,120,403
Stable Foods Inc.2,210,7922,210,792
Spaced Food Inc.355,110355,110
Engine Media (UMG)56,37710,244
Fantasy Aces9,470−
Total Equity Investments27,889,26026,783,657

Short-term loans

As at March 31, 2022 the Company’s short-term loans consist of the following:

 March 31,2022June 30, 2021
 $$
Short term loans259,609259,609
Total loan investments259,609259,609

Chief Financial Officer Appointment

Blackhawk welcomes Marc Lowenstein as the Company’s new Chief Financial Officer who will be replacing Heidi Gutte who stepped down from the CFO position on May 16th, 2022.

About Blackhawk Growth

Blackhawk Growth is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies include Sac Pharma, LeichtMind Clinics, Noble Hemp, TERP Wholesale, Blum Distributors, MindBio Therapeutics, Digital Mind, Spaced Food, Stable Foods as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For more information on Blackhawk, please visit our website at:

https://www.blackhawkgrowth.com/

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the future prospects of the business of the Company and its portfolio companies. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk’s Terp Wholesale LLC Expands Facility, Launches Retail Delivery

Blackhawk’s Terp Wholesale LLC Expands Facility, Launches Retail Delivery

Vancouver, British Columbia – TheNewswire – May 24, 2022 – Blackhawk Growth Corp. (the “Company”) (CSE:BLR); (Frankfurt:0JJ) is pleased to announce that its wholly owned subsidiary, TERP Wholesale, LLC (“TERP”) has expanded the footprint of its current facility and has capitalized on multiple strategic opportunities and significantly increased manufacturing, and distribution.

TERP Wholesale is excited to launch its new delivery service and infusion center. The company has changed licenses from a distribution license to a micro license allowing them to hold three licenses – Cultivation, Manufacturing and Retail Delivery.

Inital launch of TERP’s retail delivery service will begin in Sacramento, California and its surrounding areas. TERP will be able to deliver statewide and will expand to other cities in time. TERP also is launching a line of new products and strains from Sac Pharma Partners USA, another of the Blackhawk portfolio companies, along with its own brands like Sunshine delight. The delivery service will begin with two delivery vans and is expected to add substantial revenue. Seventy five percent of the products sold will be from TERP’s in-house production.

Terp is also pleased to announce the start-up of their infusion center. This manufacturing process that allows the company to infuse cannabis with any form of concentrate. Including but not limited to joints, moon rocks (infused cannabis flower) and wraps.

“TERP is growing rapidly,” said Frederick Pels, CEO of Blackhawk Growth Corp. “The team there has done a fantastic job growing the company and the results are beginning to show. I look forward to updating shareholders as TERP continues to prosper.”

About TERP Wholesale LLC

TERP is a fully licensed distribution center in the state of California. TERP packages and manufacturers some of the highest quality exotic brands and high THC products in the state of California. The team encompasses several distribution professionals, guided by a proven leadership with extensive experience in cannabis and quality-assured distribution. Current brands include, but are not limited to Sunshine Delight, Norcal’s Finest, California Cannabis, and Scoopz.

In addition, TERP provides supply chain solutions to the industry with the use of innovative technology, information management experts, security specialists, and sales/marketing professionals. Utilizing proven distribution methods, TERP’s model is based on a perishable supply chain strategy that emphasizes the importance of quality assurance and customer satisfaction.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes TERP Wholesale, Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods, MindBio Therapeutics, Digital Mind Technology, Blum Distributors Ltd. as well as an equity position in Gaia Grow Corp. (CSE:GAIA) .

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Corporation within the meaning of applicable securities laws. The Corporation provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Corporation ’s public filings under the Corporation’s SEDAR profile at www.sedar.com. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawk’s Mindbio Therapeutics Accelerates Global Communications Expansion Ahead of Phase 2 Clinical Trials

Blackhawk’s Mindbio Therapeutics Accelerates Global Communications Expansion Ahead of Phase 2 Clinical Trials

  • Chief Executive Colin Keating to present in London at PSYCH Symposium and to be interviewed by BBC News this week 
  • MindBio reports on the success of Plant Medicine Week in Malta and provides video recording of keynote presentation 
  • Co-founder Justin Hanka conducting non-deal broker roadshow in Canada and appearing on investor panel and delivering keynote presentation in Washington DC in May. 
  • MindBio wins prestigious communications award 
  • Recent completion of Phase 1 Clinical Trials with data analysis now underway ahead of preparations for Phase 2 Clinical Trials in patients with Major Depressive Disorder and late-stage cancer patients 

Vancouver, British Columbia – TheNewswire – May 11, 2022 – Blackhawk Growth Corp. (CSE:BLR) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report an acceleration and expansion of global market communication activities by its wholly-owned subsidiary, MindBio Therapeutics Pty. Ltd. (“MindBio”).

MindBio was recently a headline sponsor at Plant Medicine Week in Malta.  MindBio Co-Founder Justin Hanka delivered a keynote presentation to attendees outlining MindBio’s ambition to change the course of mental health treatments and prevent suicide.  He explains MindBio’s investment thesis in the sector pioneering novel psychedelic microdosing treatments through it’s world first clinical trials.  You can view the newly released video of Justin Hanka’s keynote presentation on YouTube here.

This week MindBio is in London at the PSYCH Symposium and MindBio Chief Executive Officer, Colin Keating will be presenting with other industry leaders on a panel discussing the future of psychedelic medicines and will be interviewed by BBC News.

Next week, MindBio Co-Founder Justin Hanka is conducting a non-deal roadshow with brokers and investors in Vancouver and Toronto. After that, he will head to Washington DC (USA) for the Psychedelic Therapeutics and Drug Development Conference. Mr. Hanka is participating in an investor panel with leading industry experts and is also delivering a keynote presentation on MindBio’s world first clinical trials microdosing LSD.  

MindBio remains the only organization in the world to have successfully received government approvals to administer LSD (lysergic acid diethylamide) to patients in clinical trials who take the drug out in the community and at home in the same way they would take any other medication. The Company recently announced the completion of Phase 1 clinical trials.

MindBio is accelerating its global communications strategy to advance the company’s narrative in mental health treatments and recently was recognised with a Horizon Active Gold Marketing Award for an psychedelics explainer video alongside an impressive line-up of household names, including Porsche.

“MindBio is leading the way in psychedelic microdosing clinical trials.” said Frederick Pels, CEO of Blackhawk. “With the recent successful completion of MindBio’s Phase 1 clinical trial, the MindBio team is now accelerating its global communications strategy as it unravels the data from clinical trials and prepares for Phase 2 Clinical Trials and progressing towards commercialization,”

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics, Digital Mind Therapeutics, Blum Distributors as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk Growth’s Blum Distributors Expands Facility and Starts to Fulfill Applied Myco Order

Blackhawk Growth’s Blum Distributors Expands Facility and Starts to Fulfill Applied Myco Order

Vancouver, British Columbia – TheNewswire – April 19, 2022 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its wholly-owned subsidiary, Blum Distributors Ltd. (“Blum”), white label division is now in full-operation and is expanding their facility to provide their own in-house products that are formulated with the highest quality sterile substrates, spawn, and mycelium cultures to empower both commercial and home scale growers in their mycological journey.

Blum recently signed a contract to provide a white label solution for an arm’s length company, Applied Myco. The contract guarantees a minimum order of 500 bags per month during its Phase 1 trial and is expected to increase to up to 2,000 bags per month in Phase 2 and 3 over the next 12 months. The guaranteed minimum order will generate approximately $12,500 per month in gross revenue and would increase to approximately $50,000 per month assuming an order of 2,000 bags. Gross margin on the products historically has been approximately 50%. Blum has started to fulfill this order and will update Blackhawk shareholders as the contract progresses.

With Blum’s controlled and sterilized inoculation lab, Applied Myco has entrusted its full lab operations team in regards to the creation and expansion of a 15 strain genetics and live culture library. This, in turn, will empower residential and commercial scale cultivators which is anticipated to create an additional revenue source. 

“Blum is off to a great start” said Frederick Pels, CEO of Blackhawk. “White label production is a significant step and ensures Blum will capture market share rapidly. With production and expansion occurring in tandem, I am confident that Blum will continue to grow and I look forward to updating shareholders as Blum progresses.”

Blum recently signed another sale which is expected to start delivery in April, and will see Blum expand its cultivation through a 14,000 sq ft commercial project which is guaranteed to begin with an order for 5,000 bags per month, which is expected to create gross revenue of approximately $125,000 per month.      When the cultivation centre renovations are completed, the contract provides for production increases of 5,000 per cycle to a maximum size of 50,000 bags per month. If the maximum contract deliveries are reached, the order will generate in excess of $1,000,000 per month in gross revenue for Blum, based on current sales prices.

Blum’s commercial cultivation client has recently received their building permit approvals earlier than anticipated and is now commencing the first phase of an initial 5000 bag order.

About Blum Distributors

Blum is an established mycology supplier with its own leased production facility. Blum’s operations are systemically rooted in biodiversity. They wholly-own the value chain from cultivation through to their product sales, reaching both commercial and retail partners. Their sustainability pledge is embodied in their commitment to support their partners in their own mycological journeys. Blum’s in-house product cultivation, distribution, and sales center provides them with an advantage over their competitors by reducing intermediaries. Blum fully controls the quality and purity of their products throughout the value chain, from cultivation to consumer sales. They are committed to providing the utmost highest quality supplies and solutions to empower both commercial and home scale growers in their mycological journey.

For more information regarding Blum visit their website: www.blumdistributors.com

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, Terp Wholesale, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods, and MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the future operations of Blum Distributors Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk Growth to Acquire Mycology Supplier and Cultivator – Blum Distributors

Blackhawk Growth to Acquire Mycology Supplier and Cultivator – Blum Distributors

Vancouver, British Columbia – TheNewswire – April 6, 2022 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that the Company has entered into a share purchase agreement, dated effective April 5, 2022, pursuant to which it proposes to acquire all of the outstanding share capital of Blum Distributors Ltd. (“Blum”).

Blum is an established mycology supplier with its own leased production facility. Blum’s operations are systemically rooted in biodiversity. They wholly-own the value chain from cultivation through to their product sales, reaching both commercial and retail partners. Their sustainability pledge is embodied in their commitment to support their partners in their own mycological journeys. Blum’s in-house product cultivation, distribution, and sales center provides them with an advantage over their competitors by reducing intermediaries. Blum fully controls the quality and purity of their products throughout the value chain, from cultivation to consumer sales. They are committed to providing the utmost highest quality supplies and solutions to empower both commercial and home scale growers in their mycological journey.

Blum has been in operations in its current form for over 18 months and has historically generated approximately $50,000 in gross revenue per month over 2021. The revenue base has grown in 2022, with the addition of two agreements. The first contract has Blum providing a white label solution for an arm’s length company for Applied Myco. The contract guarantees for a minimum order of 500 bags per month during its Phase 1 trial and is expected to increase to up to 2,000 bags per month in Phase 2 and 3 over the next 12 months. The guaranteed minimum order will generate approximately $12,500 per month in gross revenue, and is expected to increase to in excess of $50,000 per month in revenue. Gross margin on the products historically has been approximately 50% and this margin is expected to continue.

The next recent sale, which is expected to start delivery in     April, will see Blum expand its cultivation through a 14,000 sq ft commercial project which is guaranteed to begin with an order for 5,000 bags per month, which is expected to create gross revenue of approximately $125,000 per month.      When the cultivation centre renovations are completed, the contract has production increases of 5,000 per cycle to a maximum size of  50,000 bags per month. If the maximum contract deliveries are reached, the order will generate in excess of $1,000,000 per month in gross revenue for Blum, based on current sales prices.

“Blum’s growth continues to be impressive” said Frederick Pels, CEO of Blackhawk Growth. “The ancillary side of cultivation allows Blackhawk to be involved in the success of the industry as a whole, providing high quality and necessary substrate to the industry. I look forward to working with the team at Blum and updating our shareholders as progress develops.”        

“We at Blum Distributors are extremely excited to close this deal and grow both Blum and     Blackhawk” says Rico Gutierrez, Founder of Blum. “This opportunity will allow us to further accelerate our on-going demand of production and supplies and will assist us to expand our facility and operate at full capacity to facilitate the fast-growing mycology industry.”

Rico Gutierrez founded Blum and will continue as its CEO. Mr Gutierrez has been involved in the mycology industry for a number of years. Prior to founding Blum, he was      a  successful entrepreneur and the founder of several companies in various industries. With his experience and skill set, Rico managed to assist numerous companies with mentorship and business development.

Readers are cautioned that the above figures for revenue and margin of Blum are based on information provided by management of Blum and have not been audited or independently verified.  Actual figures may differ once an audit has taken place.

Transaction Structure

In consideration for the acquisition of all of the outstanding share capital of Blum, Blackhawk will issue 9,650,000 common shares to the existing shareholders of Blum.

The Company is at arm’s length from Blum and its shareholders. The transaction neither constitutes a fundamental change nor a change of business for the company, nor has it expected to result in a change of control of the company within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. With the acquisition, Blum will form part of the Company’s growing portfolio of investments in the life science and health care sectors. Blum’s existing management team will continue to retain responsibility for overseeing day-to-day operations. A fee of 750,000 shares will be paid to an arm’s length party for assistance with the transaction.

For more information regarding Blum visit their website: www.blumdistributors.com

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, Terp Wholesale, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods, and MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the future operations of Blum Distributors Ltd.. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk’s MindBio Therapeutics Enters its 80th and Final Patient into Phase 1 Clinical Trials and Provides Update for MindBio Spinout

Blackhawk’s MindBio Therapeutics Enters its 80th and Final Patient into Phase 1 Clinical Trials and Provides Update for MindBio Spinout

  • MindBio is about to complete the world’s first clinical trial of its kind microdosing a psychedelic medicine to patients who are prescribed the drug to take at home 
  • Independent safety audit committee review successfully competed  
  • Two Phase 2 clinical trials to follow 
  • Proposed meeting date of shareholders to approve the spinout – June 20, 2022 

Vancouver, British Columbia – TheNewswire – April 04, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that MindBio Therapeutics Pty. Ltd. (“MindBio”) has entered its 80th and final patient into its Phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide) in the largest safety trial of its kind ever to have been completed.

The global depression drugs market reached a value of US $12.7 Billion in 2020.1  MindBio is targeting this market with the most promising innovation in treating depression that has occurred since the invention of traditional modern anti-depressant medications in the mid 1980s.

Despite the investment in these traditional anti-depressant medications and their prescription by doctors and psychiatrists all over the world, the mental health crisis and prevalence of depression and related mood disorders has escalated with one of the leading causes of death in young people, being suicide.2

MindBio has also started preparation work for two Phase 2 Clinical Trials including the design of psychedelic microdosing formulations that can subsequently be manufactured under Good Manufacturing Practices (GMP) standards for use both commercially and in Clinical Trials.

MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system.  In larger doses, LSD is a hallucinogenic drug that substantially changes cognition, thinking, mood and perception, however in much smaller “microdoses”, the medicine is subperceptual, meaning that patients can take the drug without noticing its hallucinogenic effects, but still receive the medicinal benefit and get on with their normal day.

The results of this important clinical trial will form the basis for advancing the commercialization of a psychedelic microdosing regimen for safe use in the community.

In addition, Blackhawk contines to move forward on the spinout of Mindbio from Blackhawk. It has set a number of key dates for the transaction, including a proposed meeting date of shareholders to approve the spinout of June 20, 2022. Further details regarding the spinout and the meeting will be made available in an information circular mailed to shareholders of record, and posted under the profile for Blackhawk on SEDAR (www.sedar.com). Completion of the spinout remains subject to the receipt of shareholder, regulatory and court approvals.

“MindBio wants to be the first to market with a highly effective psychedelic microdosing treatment regimen and the completion of each clinical trial milestone drives us closer towards achieving our goal of changing the course of mental health treatment forever,” said Frederick Pels, CEO of Blackhawk Growth. “With progress continuing, I expect significant value to be realized once MindBio has spun out. I look forward to updating our shareholders as we make progress.”

  1. Depression Drugs Market: Global Industry Trends, Share, Size, Growth Opportunity and Forecast 2021-2026 
  2. Mortality Among Teenagers Aged 12-19 Years 

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, Terp Wholesale, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods, and MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the spinout and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk Growth’s Spaced Food Adds New Flavours and Signs Partnership Agreement with Gaia Grow’s Canadian Cannabis Laboratory TRU Extracts for Manufacturing of Blackhawk’s Spaced Food Products

Blackhawk Growth’s Spaced Food Adds New Flavours and Signs Partnership Agreement with Gaia Grow’s Canadian Cannabis Laboratory TRU Extracts for Manufacturing of Blackhawk’s Spaced Food Products

Vancouver, British Columbia – TheNewswire – March 31, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its wholly-owned subsidiary, Spaced Food has signed a partnership agreement with Gaia Grow’s TruExtracts Laboratories (“TRU”), whereby TRU will be the lead on manufacturing Spaced Food’s edibles products.

Spaced Food and TRU have agreed that TRU will staff and develop Spaced Food products as well as be responsible for marketing and sales of the completed products. In exchange for staffing and product development, TRU will receive 50% of net income earned..  

In addition to Spaced Food’s previously submitted strawberry sorbet, TRU has developed and submitted product notifications for an additional three new flavours for Spaced Food – blueberry, cherry  and mango and intends to offer a 4-pack option with all 4 flavours.

“The team at TRU have been fantastic partners” said Frederick Pels, CEO of Blackhawk Growth Corp. “From consumers to retailers, we are hearing an eager response to see Spaced Food on shelves and the team at TRU saw an opportunity to advance this product and benefit our partners at Spaced Food. I look forward to updating shareholders once these submissions are approved.”

About Spaced Food

Spaced Food is launching edibles into ORBIT using high tech, space-age science! We’ve taken our love of cannabis and combined it with a unique product that solves every problem with current cannabis edibles. Spaced Food is shelf-stable, requires no refrigeration and tastes AMAZING!

After 3 years of research and development, Spaced Food has come up with a product with excellent bioavailability that melts in your mouth, with accurate dosing. Made using the same technology used on food before sending it to space for astronauts, we lock in 98% of the nutritional value as well as 100% of the medicinal ingredients. Whether you’re 18 or 81, Spaced Food will quickly become your favourite cannabis edible!

About TruExtracts

TruExtracts Laboratories was created for high-capacity extraction and production, to meet global demand. TRU is one of Western Canada’s largest cannabis and hemp processors, with a 12,500 square foot state of the art facility in Calgary. The facility is Health Canada licensed and fully operational, with an expansion capability of an additional 16,000 additional square feet. Services include toll processing, THC, CBD extractions and isolates, as well as white label service and cannabis THC and CBD products.

For more Information, please visit their website at https://truextractslabs.com

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, Terp Wholesale, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods, and MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the spinout and future operations. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawks Mindbio Therapeutics Announces Acquisition Pathway to Accelerate Clinical Trials and Drug Development Activities

Blackhawks Mindbio Therapeutics Announces Acquisition Pathway to Accelerate Clinical Trials and Drug Development Activities

Vancouver, British Columbia – TheNewswire – March 15, 2022 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report that MindBio Therapeutics (“MindBio”) has co-invested in Quantified Citizen’s (quantifiedcitizen.com) latest funding round with other notable investors around the world. The investment was funded from MindBio existing working capital.

Quantified Citizen is a leading mobile health research platform with over 52,000 users and over 17,000 participants in their global microdosing study, which was published in the prestigious science journal Nature Scientific Reports.

MindBio is in the final completion stages of a world first Phase 1 clinical trial microdosing LSD to patients at home. The investment in Quantified Citizen will allow MindBio to further its footprint in Microdosing of psychedelics.

Quantified Citizen has created an innovative health technology platform that seeks to democratize scientific discovery through digitized health measures and a community of professional researchers and passionate citizen scientists. “We envision a world where doing scientifically valid health research is as fast and easy as creating a website, with the same global reach. Where scientific tinkering and self-examination are normalized, vastly accelerating the pace of discovery by unlocking unexamined data,” shares co-founder and CEO Eesmyal Santos-Brault.

MindBio is activily seeking new acquisition opportunities to expand its global reach of clinical trials and drug development activities. Management is regularly reviewing new opportunities that may add value to both MindBio and Blackhawk’s Digital Mind Technologies.

Justin Hanka, Founder of MindBio says “since MindBio is on path to spin out of Blackhawk and list on the CSE, now is an opportune time to cast our net and find acquisitions that can accelerate our path to commercializing new treatments for mental health conditions.”

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods Co., MindBio Therapeutics, Digital Mind Technologies as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.